2-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole | 863330-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole
• 英文别名: 2-Bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1h-benzimidazole；2-[(2-bromobenzimidazol-1-yl)methoxy]ethyl-trimethylsilane
• CAS: 863330-23-8
• 化学式: C₁₃H₁₉BrN₂OSi
• 分子量: 327.296
• InChiKey: VAECFKIXOQUIJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.11
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole 在 盐酸 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-(4-bromo-1H-pyrazol-1-yl)-1H-benzo[d]-imidazole
  参考文献：
  名称：

  Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c00693
• 作为产物：
  描述：

  2-(三甲基硅烷基)乙氧甲基氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.25h， 以74%的产率得到2-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  [EN] HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  [FR] DÉRIVÉS D' HYDANTOINE POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES

  摘要：

  该发明涉及式（1）化合物或其药用可接受的盐、溶剂合物或异构体，可用于治疗由MMPs、ADAMs、TACE、TNF-或其组合介导的疾病或症状。

  公开号：

  WO2006019768A1

文献信息

• [EN] ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS<br/>[FR] COMPOSÉS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS À CORONAVIRUS, PICORNAVIRUS ET NOROVIRUS
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2021252491A1

  公开（公告）日：2021-12-16

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating coronavirus, Picomavirus and Norovims infections with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本文提供了式（I）的化合物或其药用盐，包括包含本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗冠状病毒、皮科病毒和诺如病毒感染的方法。
• [EN] 4-ACYL-PIPERAZINES AS ANTI-VIRAL AGENTS<br/>[FR] 4-ACYL-PIPERAZINES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2005079799A1

  公开（公告）日：2005-09-01

  Anti-viral agents of Formula (I) wherein: A represents hydroxy or -NH2; D represents aryl or heteroaryl; E represents hydrogen, straight or branched chain C1-6alkyl, -CO2R1, -C(O)R1a, -C(O)NR2R3, -SO2R1, aryl, arylC1-3alkyl, heteroaryl, heteroarylC1-3alkyl, heterocyclyl or heterocyclylC1-3alkyl; R1 is selected from the group consisting of C1-6alkyl, aryl, arylC1-3alkyl, heteroaryl, heteroarylC1-3alkyl, heterocyclyl or heterocyclylC1-3alkyl; R1a is selected from the group consisting of C1-6alkyl, aryl, arylC1-3alkyl, heteroaryl, heteroarylC1-3alkyl, heterocyclyl or heterocyclylC1-3alkyl; R2 and R3 are independently selected from hydrogen, C1-6alkyl, aryl and heteroaryl; or R2 and R3 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; G represents C1-6alkyl, heterocyclylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; and salts, solvates and esters thereof; provided that when A is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.

  公式（I）的抗病毒药物，其中：A代表羟基或-NH2; D代表芳基或杂芳基; E代表氢、直链或支链C1-6烷基、-CO2R1、-C（O）R1a、-C（O）NR2R3、-SO2R1、芳基、芳基C1-3烷基、杂芳基、杂芳基C1-3烷基、杂环基或杂环基C1-3烷基; R1从C1-6烷基、芳基、芳基C1-3烷基、杂芳基、杂芳基C1-3烷基、杂环基或杂环基C1-3烷基中选择; R1a从C1-6烷基、芳基、芳基C1-3烷基、杂芳基、杂芳基C1-3烷基、杂环基或杂环基C1-3烷基中选择; R2和R3独立地选择氢、C1-6烷基、芳基和杂芳基; 或R2和R3与它们附着的氮原子一起形成5或6成员饱和环状基团; G代表C1-6烷基、杂环基C1-3烷基、芳基C1-3烷基或杂芳基C1-3烷基; 以及它们的盐、溶剂化合物和酯; 假设当A酯化形成-OR时，R从直链或支链烷基、芳基烷基、芳氧基烷基或芳基中选择，那么R不是叔丁基; 提供了它们的制备过程、包含它们的制药组合物以及在HCV治疗中使用它们的方法。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20240190901A1

  公开（公告）日：2024-06-13

  Provided are compounds comprising as a central moiety a 6-membered aromatic ring which is fused to a 5-membered heterocyclic ring comprising at least two nitrogen atoms. Also provided are formulations comprising these compounds. Further provided are organic light emitting devices (OLEDs) as well as related consumer products that utilize these compounds.
• [EN] PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DÉRIVÉ DES PLAQUETTES (PDGFR) ALPHA ET LEURS UTILISATIONS
  申请人：[en]FREQUENCY THERAPEUTICS, INC.

  公开号：WO2023081923A1

  公开（公告）日：2023-05-11

  The present disclosure provides compounds that can specifically target a PDGFRα, and thereby, reduce and/or inhibit the activation of the receptor ("PDGFRα inhibitor"). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PDGFRα inhibitors.
• [EN] HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS D' HYDANTOINE POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：SCHERING CORP

  公开号：WO2006019768A1

  公开（公告）日：2006-02-23

  This invention relates to compounds of Formula (1) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF- or combinations thereof.

  该发明涉及式（1）化合物或其药用可接受的盐、溶剂合物或异构体，可用于治疗由MMPs、ADAMs、TACE、TNF-或其组合介导的疾病或症状。